Ginkgo Bioworks Holdings (DNA) Other Non Operating Income (2021 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Other Non Operating Income came in at -$4.8 million in Q1 2026, down 111.78% YoY from $40.5 million in Q1 2025, and down 196.11% on a QoQ basis from $5.0 million in Q2 2025.
Analysis
Ginkgo Bioworks Holdings (DNA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 6 years of Other Non Operating Income data on file, last reported at -$4.8 million in Q1 2026.
- Quarterly Other Non Operating Income fell 111.78% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193000.0 (down 91.27% YoY) and the FY2024 annual result came in at -$1.5 million, up 94.77% from the prior year.
- Other Non Operating Income eased to -$4.8 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $15.9 million in Q1 2022 to a low of -$33.8 million in Q4 2023.
- A 5-year average of -$2.4 million and a median of $1.7 million in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 189.22% — and 2025, when it plunged 118.56%.
- Tracing DNA's Other Non Operating Income over 5 years: stood at -$31.9 million in 2022, then decreased by 5.91% to -$33.8 million in 2023, then soared by 95.58% to -$1.5 million in 2024, then jumped by 432.31% to $5.0 million in 2025, then plunged by 196.11% to -$4.8 million in 2026.
- The last three Other Non Operating Income figures came in at -$4.8 million (Q1 2026), $5.0 million (Q2 2025), and -$2.2 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 430.38 Mn | 345.84 Mn | 18.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | -4.77 Mn |
| Dec 31, 2025 | -10.64 Mn |
| Sep 30, 2025 | 9.26 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | -2.25 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Sep 30, 2024 | -1.57 Mn |
| Jun 30, 2024 | 5.95 Mn |
| Mar 31, 2024 | 12.12 Mn |
| Dec 31, 2023 | -47.74 Mn |
| Sep 30, 2023 | -16.52 Mn |
| Jun 30, 2023 | 10.90 Mn |
| Mar 31, 2023 | 10.86 Mn |
| Dec 31, 2022 | 43.02 Mn |
| Sep 30, 2022 | 15.99 Mn |
| Jun 30, 2022 | -22.84 Mn |
| Mar 31, 2022 | 82.59 Mn |
| Dec 31, 2021 | 79.06 Mn |
| Sep 30, 2021 | -75.94 Mn |